Design and optimization of a substituted amino propanamide series of renin inhibitors for the treatment of hypertension

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 7, 2010, Pages 2204-2209

  Chen, Austin ^a   Bayly, Christopher ^a   Bezençon, Olivier ^c   Richard Bildstein, Sylvia ^c   Dubé, Daniel ^a   Dubé, Laurence ^a   Gagné, Sébastien ^a   Gallant, Michel ^a   Gaudreault, Mireille ^a   Grimm, Erich ^a   Houle, Robert ^a   Lacombe, Patrick ^a   Laliberté, Sébastien ^a   Lévesque, Jean François ^a   Liu, Suzanna ^a   MacDonald, Dwight ^a   Mackay, Bruce ^a   Martin, David ^a   McKay, Dan ^a   Powell, David ^a   Remeň, L'uboš ^c   Soisson, Stephen ^b   Toulmond, Sylvie ^a   more..

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^b MERCK RESEARCH LABORATORIES   (United States)

^c ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

Anti hypertensive; Inhibitor; Protease; Renin

Indexed keywords

ANTIHYPERTENSIVE AGENT; CYTOCHROME P450 3A4; PROPIONAMIDE DERIVATIVE; RENIN INHIBITOR; SIMVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG INHIBITION; DRUG STRUCTURE; EXPERIMENTAL MODEL; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STRUCTURE ACTIVITY RELATION; TRANSGENIC RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CRYSTALLOGRAPHY, X-RAY; DOGS; HUMANS; HYPERTENSION; MODELS, MOLECULAR; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RENIN; STRUCTURE-ACTIVITY RELATIONSHIP;

RATTUS;

EID: 77949486219     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.02.036     Document Type: Article

References (24)

1. Zaman M.A., Oparil S., and Calhoun D.A. Nat. Rev. Drug Disc. 1 (2002) 621
2. Weber M.A. Am. J. Hypertens. 5 (1992) 247S
3. Rosenburg, S. H.; Boyd, S. A. In Antihypertensive Drugs, Van Zweiten, P. A.; Greelee, W. J., Eds.; 1998, pp 77-111.
4. http://www.cdc.gov./nchs/data/hus/hus04trend.pdf#067.
5. Cooper M.E. Am. J. Hypertens. 17 (2004) 16S
6. Norris K., and Vaughn C. Expert Rev. Cardiovasc. Ther. 1 (2003) 51
7. Greenlee W.J. Med. Res. Rev. 10 (1990) 173
8. Rosenburg S.H. Prog. Med. Chem. 32 (1995) 37
9. Jensen C., Herold P., and Brunner H.R. Nat. Rev. Drug Disc. 7 (2008) 399
10. Tice C.M. Annu. Rep. Med. Chem. (2006) 155
11. Viera E., Binggeli A., Breu V., Bur D., Fischli W., Guller R., Hirth G., Marki H.P., Muller M., and Oefner C. Bioorg. Med. Chem. Lett. 9 (1999) 1397
12. Holsworth D.D., Cai C., Cheng X.M., Cody W.L., Downing D.M., Erasga N., Lee C., Powell N.A., Edmunds J.J., Stier M., Jalaie M., Zhang E., McConnell P., Ryan M.J., Bryant J., Li T., Kasani A., Hall E., Subedi R., Rahim M., and Maiti S. Bioorg. Med. Chem. Lett. 16 (2006) 2500
13. Akatsuka, H.; Sugama, H.; Awai, N.; Kawaguchi, T.; Takahashi, Y.; Iijima, T.; Shen, J.; Xia, G.; Xie, J. WO Patent 2008/153182 A1, 2008.
14. Maibaum, J. K.; Lorthiois, E. L. J.; Buehlmayer, P. WO Patent 2007/144128 A1, 2007.
15. Bezençon O., Bur D., Weller T., Richard-Bildstein S., Remeň L., Sifferlen T., Corminboeuf O., Grisostomi C., Boss C., Prade L., Delahaye S., Trieber A., Strickner P., Binkert C., Hess P., Steiner B., and Fischli W. J. Med. Chem. 52 (2009) 3689
16. Yokokawa F., and Maibaum J. Expert Opin. Ther. Patents 18 (2008) 581
17. Powell N.A., Ciske F.L., Cai C., Holsworth D.D., Mennen K., Van Huis C.A., Jalaie M., Day J., Mastronardi M., McConnell P., Molchalkin I., Zhang E., Ryan M.J., Bryant J., Collard W., Ferreira S., Gu C., Collins R., and Edmunds J.J. Bioorg. Med. Chem. Lett. 15 (2007) 5912
18. Okano T., Harada N., and Kiji J. Bull. Chem. Soc. Jpn. 67 (1994) 2329
19. Corey E.J., and Kuwajima I. Tetrahedron Lett. (1972) 487
20. 50 was determined by curve fitting software. Plasma assay: citrate-plasma from human volunteers was pooled, aliquoted and stored frozen at -20 °C. Renin activity in pooled plasma was supplemented with recombinant human renin (150 pg/mL final concentration) in order to increase the readout of the assay. Five microlitre of renin inhibitors, at various concentrations in DMSO, was added to 80 μL of a mixture (7:1) of human plasma and a fast trapping primary AngI antibody (anti-AngI: AS1, bleed 6, pre-diluted 1:10 in horse serum) diluted initially 1:26.5 in assay buffer (PBS1X, 1 mM EDTA, 0.1% BSA, pH 7.4) and then diluted 1:3.3 in 3 M Tris, 200 mM EDTA, pH 7.2 (final anti-serum dilution 1:50,000) and was incubated at 37 °C for 2 h. As was done in the buffer assay, 12 μL of the renin reaction (or standards in the assay buffer) were measured for AngI accumulation by immunoassay.
21. Takakusa H., Masumoto H., Yukinaga H., Makino C., Nakayama S., Okazaki O., and Sudo K. Drug Metab. Disp. 36 (2008) 1770
22. Hintermann T., and Seebach D. Helv. Chim. Acta 81 (1998) 2093
23. Huang S.L., Mancuso A.J., and Swern D. J. Org. Chem. 43 (1978) 2480
24. Hess P., Clozel M., and Clozel J.-P. J. Appl. Physiol. 81 (1996) 1027